ATE515189T1 - Verfahren zur herstellung von antigenspezifischen lymphozyten - Google Patents

Verfahren zur herstellung von antigenspezifischen lymphozyten

Info

Publication number
ATE515189T1
ATE515189T1 AT02794219T AT02794219T ATE515189T1 AT E515189 T1 ATE515189 T1 AT E515189T1 AT 02794219 T AT02794219 T AT 02794219T AT 02794219 T AT02794219 T AT 02794219T AT E515189 T1 ATE515189 T1 AT E515189T1
Authority
AT
Austria
Prior art keywords
lymphocytes
cells
antigen
generation
resulting
Prior art date
Application number
AT02794219T
Other languages
English (en)
Inventor
Lili Yang
Parijs Luk Van
David Baltimore
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Application granted granted Critical
Publication of ATE515189T1 publication Critical patent/ATE515189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02794219T 2001-12-10 2002-12-10 Verfahren zur herstellung von antigenspezifischen lymphozyten ATE515189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33937501P 2001-12-10 2001-12-10
US39480302P 2002-07-08 2002-07-08
PCT/US2002/039527 WO2003050262A2 (en) 2001-12-10 2002-12-10 Method for the generation of antigen-specific lymphocytes

Publications (1)

Publication Number Publication Date
ATE515189T1 true ATE515189T1 (de) 2011-07-15

Family

ID=26991603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794219T ATE515189T1 (de) 2001-12-10 2002-12-10 Verfahren zur herstellung von antigenspezifischen lymphozyten

Country Status (5)

Country Link
US (1) US20030152559A1 (de)
EP (1) EP1450611B1 (de)
AT (1) ATE515189T1 (de)
AU (1) AU2002359666A1 (de)
WO (1) WO2003050262A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050238626A1 (en) * 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
US20090217403A1 (en) * 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
CA2630348C (en) * 2005-11-17 2016-01-12 Stichting Voor De Technische Wetenschappen Inducible expression systems
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
WO2009058012A1 (en) * 2007-11-01 2009-05-07 Deltacell B.V. Means and methods for eliciting an immune response
EP2389443B1 (de) 2009-01-23 2018-11-14 Roger Williams Hospital Retrovirale vektoren kodierend für multiple stark homologe nichtvirale polypeptide und ihre verwendung
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2011130491A2 (en) 2010-04-14 2011-10-20 Roger Williams Medical Center Methods and compositions for treating hiv
WO2012072814A1 (en) 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2014183056A1 (en) * 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer
GB201719169D0 (en) * 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods

Also Published As

Publication number Publication date
AU2002359666A1 (en) 2003-06-23
WO2003050262A3 (en) 2004-02-12
US20030152559A1 (en) 2003-08-14
EP1450611A4 (de) 2005-12-07
EP1450611B1 (de) 2011-07-06
WO2003050262A2 (en) 2003-06-19
EP1450611A2 (de) 2004-09-01
AU2002359666A8 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
AU2002359666A8 (en) Method for the generation of antigen-specific lymphocytes
Bode et al. First isolates of infectious human Borna disease virus from patients with mood disorders
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
Duan et al. Targeting NK cells for HIV-1 treatment and reservoir clearance
AR032871A1 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
DK1093465T3 (da) Fremgangsmåde til frembringelse eller forögelse af en T-cellerespons mod en målcelle ved brug af kompleks omfattende et HLA klasse I molekyle og et tilkoblingsorgan
Yao et al. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine
Yun et al. Mediation of osseointegration, osteoimmunology, and osteoimmunologic integration by tregs and macrophages: a narrative review
Santini et al. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines
JP2006180865A (ja) マラリアペプチド
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
Lam et al. Highlight of 2023: Unlocking the therapeutic potential of natural killer cells—advances in adaptive functions, cellular engineering and immunotherapy.
ATE351904T1 (de) Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen
Jin et al. The Epitope Basis of Embryonic Stem Cell‐Induced Antitumor Immunity against Bladder Cancer
Phua et al. Influenza A virus derived NS1 enhances translation of HPLC purified mRNA and interferon adjuvanted mRNA vaccination
Hawse et al. An immunology primer for computational modelers
Sun et al. MHC class I multimers
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties